logo
Twitter
Discord
Email
logo
Pfizer Inc.

Pfizer Inc.

NYSE•PFE
CEO: Dr. Albert Bourla D.V.M., Ph.D.
Sector: Healthcare
Industry: Drug Manufacturers - General
Listing Date: 1972-06-01
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Contact Information
66 Hudson Boulevard East, New York, NY, 10001-2192, United States
212-733-2323
www.pfizer.com
Market Cap
$145.84B
P/E (TTM)
14.8
46.4
Dividend Yield
6.7%
52W High
$27.69
52W Low
$20.92
52W Range
70%
Rank23Top 9.4%
5.8
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 5.8 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q3 2025 Data

Revenue

$16.65B-5.92%
4-Quarter Trend

EPS

$0.62-21.45%
4-Quarter Trend

FCF

$4.00B-34.01%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Nine Months Net Income Rises Net income attributable to common shareholders reached $9.42B for nine months, increasing from $7.62B in prior year period.
Operating Cash Flow Strengthens Cash provided by operating activities totaled $6.36B for nine months, showing an increase over the $6.02B generated last year.
Biopharma Revenue Declines Moderated Biopharma total revenues were $44.06B for nine months, an operational decline of 2% compared to $44.99B previously.
Major R&D In-Licensing Charge Recorded $1.35B charge in Q3 2025 for exclusive global in-licensing agreement with 3SBio for SSGJ-707 compound.

Risk Factors

COVID Product Demand Decreasing Operational revenue decline driven by lower Paxlovid demand due to reduced infection rates and narrower Comirnaty recommendations.
Patent Expiries Looming Anticipate more significant revenue impact from patent-based and regulatory exclusivity expirations between 2026 through 2030.
Legal Contingencies Uncertainty Subject to numerous contingencies including patent litigation and product liability claims; loss estimation remains complex.
Tax Rate Fluctuations Impact Effective tax rate for continuing operations was negative (6.5)% in Q3 2025 due to jurisdictional mix and tax benefits.

Outlook

Cost Realignment Program Progress Multi-year cost realignment program targets $5.7B net cost savings through 2027, focusing on productivity and R&D efficiency.
Metsera Acquisition Planned Definitive agreement signed to acquire Metsera, a clinical-stage company, for $4.9B enterprise value, pending closing conditions.
Strategic R&D Focus Shift Combined former Oncology R&D divisions into a single Pfizer R&D organization to sharpen discovery and development focus.
Capital Allocation Priorities Maintained Framework centers on growing dividend, reinvesting in business, and making share repurchases after prudent balance sheet deleveraging.

Peer Comparison

Revenue (TTM)

Merck & Co., Inc.MRK
$64.24B
+1.7%
Pfizer Inc.PFE
$62.79B
+3.9%
Bristol-Myers Squibb CompanyBMY
$48.03B
+1.3%

Gross Margin (Latest Quarter)

Merck & Co., Inc.MRK
81.9%
+6.4pp
Gilead Sciences, Inc.GILD
79.8%
+0.7pp
Pfizer Inc.PFE
74.9%
+14.1pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
MRK$271.83B14.338.9%31.9%
AMGN$177.92B25.496.2%60.6%
DHR$168.98B47.96.9%21.1%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-2.1%
Flat Growth
4Q Net Income CAGR
106.4%
Profitability Improved
Cash Flow Stability
75%
Volatile Cash Flow

Research & Insights

Next earnings:Feb 3, 2026
|
EPS:$0.58
|
Revenue:$16.81B
Reports
All Years
  • Form 10-Q - Q3 2025

    Period End: Sep 28, 2025|Filed: Nov 4, 2025|
    Revenue: $16.65B-5.9%
    |
    EPS: $0.62-21.4%
    Meet
  • Form 10-Q - Q2 2025

    Period End: Jun 29, 2025|Filed: Aug 5, 2025|
    Revenue: $14.65B+10.3%
    |
    EPS: $0.51+12042.9%
    Miss
  • Form 10-Q - Q1 2025

    Period End: Mar 30, 2025|Filed: May 5, 2025|
    Revenue: $13.72B-7.8%
    |
    EPS: $0.52-5.2%
    Miss
  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 27, 2025|
    Revenue: $63.63B+6.8%
    |
    EPS: $1.42+278.2%
    Beat
  • Form 10-Q - Q3 2024

    Period End: Sep 29, 2024|Filed: Nov 4, 2024|
    Revenue: $17.70B+31.2%
    |
    EPS: $0.79-286.2%
    Beat
  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 5, 2024|
    Revenue: $13.28B+2.1%
    |
    EPS: $0.00-99.0%
    Miss
  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 8, 2024|
    Revenue: $14.88B-19.5%
    |
    EPS: $0.55-43.9%
    Beat
  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 22, 2024|
    Revenue: $59.55B-40.6%
    |
    EPS: $0.38-93.3%
    Beat